Sarepta Therapeutics Stock
€17.29
Your prediction
Sarepta Therapeutics Stock
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
Cons
Performance of Sarepta Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sarepta Therapeutics | -2.550% | -0.832% | 51.889% | -86.564% | -85.015% | -83.855% | -85.651% |
Regeneron Pharmaceuticals Inc. | 2.050% | 6.156% | 10.525% | -51.473% | -23.773% | -16.299% | 0.448% |
Exact Sciences | 0.560% | 4.439% | -2.513% | -24.594% | -25.800% | 10.020% | -40.670% |
Incyte Corp. | 0.780% | 0.838% | 29.424% | 29.649% | 13.512% | 0.498% | -6.505% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Sarepta Therapeutics, traded under the symbol AVII, reflect a complex picture shaped by its positioning in the Biotechnology and Medical Research sector. The company has been heavily investing in research and development, which is crucial in this industry. However, the resulting financial statements indicate significant losses, raising queries about its future performance and viability. While the potential for groundbreaking advancements in treatment options exists, investors must weigh the current financial challenges against future possibilities carefully.
Market Capitalization: With a market capitalization of approximately $12.9 billion, Sarepta has a robust presence in the biotech sector. This positioning facilitates investment opportunities and potential market confidence, reflecting the belief in its future innovations.
Revenue Growth: Revenues for Sarepta totaled about $1.4 billion in the most recent twelve months (TTM). This suggests that the company has viable product lines, delivering growth opportunities despite the ongoing losses.
Comments
News

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment

Sarepta Therapeutics Stock: FDA Reverses Course on Therapy Ban
Sarepta Therapeutics has experienced a whirlwind week as the FDA unexpectedly reversed its recommendation to suspend shipments of Elevidys, the company's gene therapy for Duchenne muscular

Is This Stock a Buy After Soaring by 20% in 1 Day?
It's been a rough year for Sarepta Therapeutics (NASDAQ: SRPT), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues